FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced non-small cell lung cancer whose disease has progressed after other treatments and with tumors that express the protein PD-L1.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
